Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 12/20 | 0.56 |
| ▸ | GSK3B | P49841 | 9/20 | 0.56 |
| ▸ | SRC | P12931 | 6/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.44 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 2/20 | 0.38 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2205082 | 0.91 | AURKA (0.67) | AURKAGSK3BSRCAURKBHTT | |
| SCHEMBL2204069 | 0.87 | AURKA (0.53) | AURKAGSK3BSRCAURKBMAPT | |
| SCHEMBL2204733 | 0.87 | AURKA (0.57) | AURKAGSK3BSRCAURKBMAPT | |
| SCHEMBL2203861 | 0.85 | SRC (0.50) | AURKAGSK3BSRCMAPTKDM4E | |
| SCHEMBL2205414 | 0.83 | AURKA (0.47) | AURKAGSK3BSRCAURKBMAPT | |
| SCHEMBL12430623 | 0.82 | AURKA (0.83) | AURKAGSK3BSRCAURKBGSK3A | |
| SCHEMBL2204796 | 0.82 | AURKA (0.52) | AURKAGSK3BSRCAURKBMAPT | |
| SCHEMBL786285 | 0.80 | AURKA (0.69) | AURKAGSK3BSRCAURKBMAPT | |
| SCHEMBL2205392 | 0.78 | AURKA (0.70) | AURKAGSK3BSRCAURKB | |
| SCHEMBL2206599 | 0.77 | APP (0.50) | AURKAGSK3BSRCAURKBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4234435-B2 | — | — | 2009-03-04 | — | — | JP | claimed |
| EP-1355905-B1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2007-02-21 | — | — | EP | claimed |
| JP-2004519479-A | — | — | 2004-07-02 | — | — | JP | claimed |
| US-6653300-B2 | Anticancer agents; autoimmune diseases | VERTEX PHARMACEUTICALS INCORPORATED | 2003-11-25 | — | — | US | claimed |
| EP-1355905-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2003-10-29 | — | — | EP | claimed |
| US-20030004161-A1 | Pyrazole compounds useful as protein kinase inhititors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-01-02 | — | — | US | claimed |
| WO-2002068415-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-09-06 | — | — | WO | claimed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| US-20030105090-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-06-05 | — | — | US | disclosed |
| US-20030078275-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-24 | — | — | US | disclosed |
| US-20030055068-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-03-20 | — | — | US | disclosed |
| US-20030036543-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-02-20 | — | — | US | disclosed |
| US-20030004161-A1 | Pyrazole compounds useful as protein kinase inhititors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-01-02 | — | — | US | disclosed |
| WO-2002066461-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002057259-A2 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004161-A1 | Pyrazole compounds useful as protein kinase inhititors | AURKC, AURKA, GSKIP | AURKA 2/4885GSK3B 4/4885SRC 732/4885 |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | AURKA 1018/4885GSK3B 4217/4885SRC 1484/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | AURKA 1514/4885GSK3B 4568/4885SRC 1586/4885 |
| US-20030055068-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | AURKA 2/4885GSK3B 3/4885SRC 643/4885 |
| US-20030078275-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | AURKA 2/4885GSK3B 3/4885SRC 499/4885 |
| US-20030105090-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, GSK3B, AURKA | AURKA 3/4885GSK3B 2/4885SRC 378/4885 |
| US-20030036543-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | AURKA 2/4885GSK3B 3/4885SRC 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.